stockrowQIAGEN N.V.
QGEN Healthcare Diagnostics & Research
QIAGEN N.V.’s revenue for fiscal 2025 (year ended December 2025) was $2.1 billion, up 5.65% from fiscal 2024.
- Revenue
- +0.28%
- EPS
- +7.94%
- Free cash flow
- +30.5%
- Total debt
- +13.8%
Quarter to June 2026, against a year earlier
Follow QGEN
Alert me
QIAGEN N.V. (QGEN) Free cash flow margin
QIAGEN N.V.'s free cash flow margin over the twelve months to 30 June 2026 was 21.0%, down 0.4 percentage points from fiscal 2025 (21.4%). Over the past ten years it has ranged from 3.67% (fiscal 2019) to 26.4% (fiscal 2022); the current reading is higher than 82% of that period. That is above the Diagnostics & Research industry median of 0.00% and above the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Embed this chart
Annual newest first
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2025 | 21.4% | (3.99) |
| FY2024 | 25.4% | 10.30 |
| FY2023 | 15.1% | (11.34) |
| FY2022 | 26.4% | 7.22 |
| FY2021 | 19.2% | 11.00 |
| FY2020 | 8.21% | 4.54 |
| FY2019 | 3.67% | (10.23) |
| FY2018 | 13.9% | 2.44 |
| FY2017 | 11.5% | (7.06) |
| FY2016 | 18.5% | 2.90 |
Against its own ten years
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| MEDP Medpace Holdings, Inc. compare | 23.5% |
| QGEN QIAGEN N.V. | 21.0% |
| RVTY Revvity Inc. compare | 20.5% |
| ICLR ICON PLC compare | 10.4% |
| CRL Charles River Laboratories International, Inc. compare | 10.1% |
| BLLN BillionToOne, Inc. compare | 7.76% |
| RDNT RadNet, Inc. compare | 3.28% |
| GH Guardant Health, Inc. compare | −18.2% |
| GRAL GRAIL, Inc. compare | −187.3% |
| Diagnostics & Research industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue
More on QGEN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement